OMS 824

Drug Profile

OMS 824

Alternative Names: OMS-643762; OMS-824

Latest Information Update: 28 Jun 2016

Price : $50

At a glance

  • Originator Nura
  • Developer Omeros Corporation
  • Class Antipsychotics
  • Mechanism of Action Phosphodiesterase 10A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Suspended Schizophrenia

Most Recent Events

  • 15 Mar 2016 Omeros plans to submit a phase II clinical trial protocol to the US FDA, for the treatment of Schizophrenia (Omeros, Form 10-K, March 2016)
  • 08 Mar 2016 Phase-II development for Huntington's disease and Schizophrenia is ongoing in USA (PO)
  • 21 Oct 2014 Omeros suspends the phase II trial in Huntington's disease; the company works with the US FDA to continue the trial (NCT02074410)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top